Latest MicroRNA Stories
NEW YORK, Nov. 17, 2014 /PRNewswire/ -- Kalorama Information believes that a new consortium will greatly enhance the use of miRNA (or microRNA).
- Treatment with RG-012 Protects Kidney Function and Demonstrates Additive Therapeutic Effect with Emerging Standard of Care in Preclinical Model of Alport Syndrome - LA JOLLA, Calif.,
The global market for microRNA (miRNA) research tools, services, diagnostics and drug discovery is expected to reach $1 billion by 2019, at a compound annual growth rate (CAGR) of 12.6% for the
LA JOLLA, Calif., Nov. 6, 2014 /PRNewswire/ -- Regulus Therapeutics Inc.
- Demonstrated Human Proof-of-Concept; 'Clinical Map Initiative' Updated - LA JOLLA, Calif., Nov.
LA JOLLA, Calif., Oct. 30, 2014 /PRNewswire/ -- Regulus Therapeutics Inc.
Data Supportive of GEN-2, an RNAi Carrier for Therapeutic Treatment of Lung Cancer LAWRENCEVILLE, N.J., Oct.
- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform - LA JOLLA, Calif., Oct.
-New Preclinical Results Increase Mechanistic Understanding of Targeting miR-103/107 for Metabolic Disorders and miR-21 for Renal Dysfunction in Alport Syndrome Patients- LA JOLLA, Calif.,
-Newly Allowed Claims Demonstrate Regulus' Leadership in the microRNA Field- LA JOLLA, Calif., Sept.
- A gift; a largess; a gratuity; a present; a dole.